ScreenerHero

NTHINeOnc Technologies Holdings Inc. Common Stock

NAS · US · Healthcare · Biotechnology · neonc.com
4.675USD+0.97%Mkt Cap: 121.25M $P/E: —

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap121.25M $
Enterprise Value114.84M $
Revenue (TTM)39.99K $
Gross Profit39.99K $
Net Income (TTM)-62.15M $
Revenue/Share0.0020 USD
Last Price4.675 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees5
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.53
PEG—
EV/EBITDA—
EV/Revenue2871.62
P/S2957.48
P/B-5.23
EPS (TTM)-2.12
EPS (Forward)-1.01
52W Range
3.00517% of range12.99
52W High12.99 USD
52W Low3.005 USD
Profitability
Gross Margin100.00%
Oper. Margin-104418.90%
EBITDA Margin0.00%
Profit Margin-155404.38%
ROE354.96%
ROA-2200.93%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-20.36M $
CapEx (TTM)500.00K $
FCF Margin13506.62%
FCF Yield4.45%
Net Debt-1.65M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.36
Current Ratio0.18
Quick Ratio0.09
Book Value/Sh-0.8720 USD
Cash/Share0.0790 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)16.00 USD
Upside (mean)+242.2%
Target Range13.00 USD – 20.00 USD
$13.00+242.2% to mean$20.00
# Analysts3
Ownership
Shares Out.25.94M
Float8.46M
Insiders58.90%
Institutions12.20%
Short Interest
Short Ratio9.5d
Short % Float5.70%
Short % Out.2.38%
Shares Short617.95K
Short (prev mo.)391.11K
Technical
SMA 504.126 (+13.3%)
SMA 2006.828 (-31.5%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)185.88K
Avg Vol (10d)476.60K
Technical Indicators
RSI (14)57.0
MACD0.2155
MACD Signal0.0562
MACD Hist.+0.1593
BB Upper5.202 USD
BB Middle3.892 USD
BB Lower2.582 USD
BB Width67.31%
ATR (14)0.5830 USD
Vol Ratio (20d)0.66x